menu search

Greenwich lifesciences reveals 5-year data for gp2 immunotherapy in breast cancer settings

Greenwich LifeSciences Inc (NASDAQ: GLSI) has published new GP2 Phase 2b trial data. The trial enrolled HER2 positive patients, who received a stand...

December 9, 2021, 1:19 pm

Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...

December 8, 2021, 1:27 pm

Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...

December 8, 2021, 1:27 pm

Novartis' new kisqali data shows consistent overall survival benefit across metastatic breast cancer settings

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic br...

December 8, 2021, 1:27 pm

1 cancer stock on buyout watch in 2022

Cardiff Oncology is a prime takeover target heading into 2022....

November 21, 2021, 9:45 am

1 cancer stock on buyout watch in 2022

Cardiff Oncology is a prime takeover target heading into 2022....

November 21, 2021, 9:45 am

1 cancer stock on buyout watch in 2022

Cardiff Oncology is a prime takeover target heading into 2022....

November 21, 2021, 9:45 am

Mersana highlights new preclinical data for xmt-2056 cancer settings

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...

October 8, 2021, 12:52 pm

Mersana highlights new preclinical data for xmt-2056 cancer settings

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...

October 8, 2021, 12:52 pm

Mersana highlights new preclinical data for xmt-2056 cancer settings

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced new preclinical data of XMT-2056. Data were presented at the AACR-NCI-EORTC Virtual Internati...

October 8, 2021, 12:52 pm


Search within

Pages Search Results: